Syneron Medical Obtains FDA Clearance And CE Mark Approval For VelaShape III

(RTTNews) - Syneron Medical Ltd. (ELOS) announced that it has received the Food and Drug Administration or FDA clearance and CE mark approval for VelaShape III, the company's new non-invasive body shaping platform. The company noted that the new platform is effective for temporary reduction in circumference of the abdomen and is also used in a wide range of other body shaping applications such as cellulite treatments.

"In a VelaShape III clinical study of forty-two patients an average abdominal circumference reduction of 2.6 cm was recorded post 10 weeks following a single treatment…."Within the same study, we uncovered that 100 percent of the patients responded to the single treatment protocol with an abdominal circumference reduction of at a least 1.5 cm, with results seen as early as two weeks," said Ruthie Amir, Global Vice President of Clinical Affairs.

The company stated that the new VelaShape III system also comes equipped with a multitude of new features designed to significantly reduce the number of treatments while reducing the percentage of non-responders. Some of these new features include increased radio-frequency power of up to 150W, sophisticated real time feedback mechanisms for consistent RF delivery independent of tissue variations and a built-in, real time tissue surface temperature sensor. The system also offers a complete range of new tip configurations for various body locations.